Publications by authors named "K Zhernosekov"
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Front Endocrinol (Lausanne)
November 2022
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation carrier-added Lu-177. PRRT has recently been developed for the treatment of neuroendocrine tumors (NETs).
View Article and Find Full Text PDFPalliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is Lu-DOTA-zoledronic acid (Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples.
View Article and Find Full Text PDFIntroduction: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties.
View Article and Find Full Text PDFProstate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Recently, albumin-binding PSMA radioligands with enhanced blood circulation were developed to increase the tumor accumulation of activity. The present study aimed at the design, synthesis and preclinical evaluation of a novel class of PSMA-targeting radioligands equipped with ibuprofen as a weak albumin-binding entity in order to improve the pharmacokinetic properties.
View Article and Find Full Text PDFArticle Synopsis
- 68Ga-DOTATATE is a peptide-based radiolabeled agent designed to target somatostatin receptors found in neuroendocrine tumors, and the study focuses on validating an organic matrix generator for its production.
- The manual synthesis process involves using 68Ga with a high radiochemical yield of 99%, with quality control measures ensuring the safe and effective preparation of clinical doses in about 35 minutes.
- The findings highlight that the 68Ga labeling process is efficient and does not require additional purification steps, making it suitable for clinical use and contributing to the growing interest in 68Ga-labeled agents in patient care.